Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Exagamglogene autotemcel by CRISPR Therapeutics for Sickle Cell Disease: Likelihood of Approval
Exagamglogene autotemcel is under clinical development by CRISPR Therapeutics and currently in Phase III for Sickle Cell Disease. According to...